Maryland’s House Bill 631, which is scheduled to take effect in October 2017, is facing a lawsuit filed by the Association for Accessible Medicines, which calls the bill unconstitutional.
Maryland’s House Bill (HB) 631, which is scheduled to take effect in October 2017, is facing a lawsuit filed by the Association for Accessible Medicines (AAM), which calls the bill unconstitutional.
AAM filed suit in a US district court in Maryland in July. The industry trade group says that the bill “grants Maryland unprecedented powers to regulate the national pharmaceutical market, violating the United States Constitution and posing harm to vulnerable patient communities.”
The bill, which targets price gouging (which the bill defines as “an unconscionable increase in the price of a prescription drug”) in the sale of off-patent or generic drugs, requires the Maryland Medical Assistance Program to notify the state’s attorney general of increase in the prices of generic or off-patent treatments, and authorizes the attorney general to:
AAM calls into question the bill’s focus on generic drugs as a way to save health costs for Maryland; according to the group, generic medications, which account for the majority of prescriptions written each year, saved Maryland $4.1 billion in 2016. The bill includes no provisions addressing the cost of patent-protected drugs.
When the Maryland legislature passed the bill, Governor Larry Hogan (R) declined to sign it, but allowed the legislation to pass into law. In a letter to the state’s Speaker of the House, Hogan expressed reservations about the bill, saying that it raised “legal and constitutional concerns,” and that he found it “troubling” that the bill did not target patent-protected drugs or medical devices. Hogan’s letter concluded with a statement that, in his view, the problem of drug pricing can only be addressed at a national or global level, and that state legislation such as HB 631 did not present a solution to the problem.
Maryland’s Attorney General Brian Frosh, however, has been a vocal supporter of HB 631, saying that the law will “give Maryland a necessary tool to combat unjustified and extreme price increases for medicines that have long been on the market and that are essential to our health and well-being.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.